GNAS c.393T>C (Q29938321)

From Wikidata

Jump to navigation Jump to search

genetic variant

T393C
c.393T>C
LEU69SER
LEU131=
I131=
RS7121
L131=

Language	Label	Description	Also known as
English	GNAS c.393T>C	genetic variant	T393C c.393T>C LEU69SER LEU131= I131= RS7121 L131=

Statements

Synonymous Variant

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/877

human chromosome 20

genomic assembly

Genome assembly GRCh37

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/877

57428713

genomic assembly

Genome assembly GRCh37

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/877

57428713

genomic assembly

Genome assembly GRCh37

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/877

biological variant of

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/877

negative therapeutic predictor for

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/1995

[Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status].

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/1995

[Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status].

fluorouracil / cisplatin combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

esophageal cancer

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/2895

GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.

positive prognostic predictor for

renal clear cell carcinoma

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/2896

The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma

chronic lymphocytic leukemia

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/2897

The GNAS1 T393C polymorphism is associated with disease progression and survival in chronic lymphocytic leukemia

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/2898

GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma

bladder urothelial carcinoma

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/2892

The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer

colorectal cancer

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/2893

GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer

negative prognostic predictor for

intrahepatic cholangiocarcinoma

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/1996

GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma

breast carcinoma

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/evidence/1997

The T393C polymorphism in the gene GNAS1 of G protein is associated with survival of patients with invasive breast carcinoma.

Identifiers

CIViC variant ID

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/877

HGVS nomenclature

NC_000020.11:g.58903752C>T

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/877

NC_000020.10:g.57478807C>T

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/877

NM_000516.4:c.393C>T

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/877

NP_000507.1:p.Ile131=

1 reference

22 January 2022

https://civic.genome.wustl.edu/links/variants/877

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q29938321&oldid=2014803995"